Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other infla…
Not yet scored
135.07 USD
Price as of 20 Oct 2026Daily close, not a live quoteLast reviewed 9 days ago
Screened 2026-10-20 · the tape above runs as of 10:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price135.07 USD at the 20 Oct 2026 close
Ethical screenNot yet scored
Last reviewed20 Oct 2026 (9 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 135.07 against the desk's fair-value range, base estimate 135.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical screen not yet scored
Price135.07 USD
Fair value135.00
Ethical score70.0/100
Our investment reviews on this name
2026-08-21Read Accumulation134.49+0.4% to today ✓Markdown gives way to Accumulation after a 52% rise in 7 weeks
2026-07-02Read Markdown88.33+52.9% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Apogee Therapeutics, Inc. holds its Accumulation at $135.07. The statistical read favours the sellers, held for 35 days.
As held on the ledger · 2026-10-20
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 35 days
Price at the screen
$135.07
Valuation
N/A trailing · -26.00 forward price to earnings
Values screen
Not scored· score 70.0
Beta
0.33
The Workings
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.94%
Below 33%
Interest-bearing debt is just 0.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
18.43%
Below 33%
Cash held in interest-bearing accounts and securities is 18.4% of assets, under the one-third limit.
Pass
Receivables
14.67%
Below 49%
Money owed to the company is 14.7% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
The Read, in Plain English
Apogee Therapeutics, clears the business-activity screen and the figures we can measure look clean, but its income-purity figure is still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-20 screen. The gold marker is the market price at the same screen. The price runs 0.1% above the base estimate.
Third-party analyst targets: 5 covering, consensus Hold. The average target sits −0% from the screen price.
Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-20 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical Biotech Priced Near Fair Value
Bringing a new biologic through trials feels like funding a long-shot film that may never reach cinemas. Apogee sits at a clinical stage with zero profit margins and a negative return on equity, yet trades almost exactly at the analysts' median target. The thin margin of safety and complete lack of financial ratio data leave little room to build conviction.
We pass because the ethical screen returns insufficient data and the opportunity rating is none. Negative forward earnings and an unknown moat make any assessment speculative rather than analytical. Without clearer numbers the position stays outside our framework.
Clinical failure, repeated capital raises and binary regulatory outcomes remain the dominant risks. Even a successful trial would still need years of cash burn before any revenue appears. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
APGE trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-27Accumulation$135.07+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 62% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (17 analysts) rates it strong buy, with a mean price target of $118. Insiders have been net sellers over the past quarter.
2026-10-12Accumulation$135.07+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (17 analysts) rates it strong buy, with a mean price target of $118. Insiders have been net sellers over the past quarter.
2026-10-02Accumulation$135.07+0.0%Entry 8
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (17 analysts) rates it strong buy, with a mean price target of $118. Insiders have been net sellers over the past quarter.
2026-09-21Accumulation$135.07+0.4%Entry 7
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (17 analysts) rates it strong buy, with a mean price target of $118. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (17 analysts) rates it strong buy, with a mean price target of $118. Insiders have been net sellers over the past quarter.
2026-07-21Markdown$134.00+51.7%Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 51.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (17 analysts) rates it strong buy, with a mean price target of $118.
2026-07-18Markdown$88.33+0.0%Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (17 analysts) rates it strong buy, with a mean price target of $118.
2026-07-17Markdown$88.33+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 96%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (17 analysts) rates it strong buy, with a mean price target of $118.
2026-07-03Markdown$88.33+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$88.33Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
